Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have haemophilia A or B with inhibitors to factor VIII or IX, respectively~* Have had a historical inhibitor level of at least five Bethesda units or have had an inadequate haemostatic response to 250 U/kg of factor VIII or IX or have had an inadequate response to FEIBA~* Require pre-planned major surgery in hospital~Exclusion Criteria:~* Have participated in or have been treated with any investigational drug other than activated recombinant human factor VII within the last thirty days~* Have been treated with any haemostatic agent, including rFVIIa, within 48 hours of preoperative dose~* Have any haemostatic disorder other than haemophilia

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous infusion (Type: EXPERIMENTAL): None
- Bolus injection (Type: EXPERIMENTAL): None
- Control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).